Table 3.
Primary NRTI and NNRTI drug resistance mutations detected at low frequency (≥2% to 20%) in baseline samples from control subjects by deep sequencing and Week 96 snapshot outcome.
| Subject Number a | Baseline HIV-1 RNA (Copies/mL) | NRTI-R b (% Frequency) | NNRTI-R c (% Frequency) | Mutant Copy Number | Week 96 Snapshot Outcome |
|---|---|---|---|---|---|
| RPV/FTC/TDF | |||||
| 1 | 3,620,000 | K65R (2.00) | -- | 72,400 | Success |
| 2 | 562,000 | -- | V108I (2.23) | 12,533 | Success |
| 3 | 535,000 | -- | E138K (2.11) | 11,289 | Success |
| 4 | 1,240,000 | -- | Y181C (2.87) | 35,588 | Success |
| 5 | 92,200 | -- | G190E (3.73) | 3,439 | Success |
| 6 | 527,000 | -- | M230I (5.31) | 27,984 | Success |
| EFV/FTC/TDF | |||||
| 7 | 61,400 | M41L (12.3) | -- | 7,552 | No data in window d |
| 8 | 2,500,000 | K219Q (2.36) | -- | 59,000 | Failure e |
| 9 | 164,000 | -- | L100I (14.6) | 23,944 | Success |
| 10 | 93,000 | -- | G190E (2.33) | 2,167 | Success |
--, no mutations. a All subjects had HIV-1 subtype B; b Primary nucleoside/nucleotide reverse transcriptase inhibitor resistance (NRTI-R) mutations are M41L, K65N/R, D67N, T69 insertion/deletion, K70E/R, L74V/I, Y115F, Q151M, M184I/V, L210W, T215Y/F, and K219E/Q/N/R in RT; c Primary non-nucleoside reverse transcriptase inhibitor resistance (NNRTI-R) mutations are L100I, K101E/P, K103N/S, V106A/M, V108I, E138A/G/K/Q/R, V179L, Y181C/I/V, Y188C/H/L, G190A/E/Q/S, H221Y, P225H, F227C, and M230I/L in RT; d Subject was lost to follow-up. HIV-1 RNA at last visit on study (Week 84) was <50 copies/mL; e Subject was lost to follow-up. HIV-1 RNA at last visit on study (Week 16) was 207 copies/mL.